Close Menu

Drug Discovery & Development

News on drug screening, clinical trials, companion diagnostics, immunotherapy, & personalized therapies in genetics, genomics, and molecular diagnostics.

Lantern Pharma is using its RADR platform to repurpose two drugs currently in clinical trials and advance a new drug in preclinical testing.

The open-label, multi-center trial will start enrolling patients in the third quarter to evaluate the safety of lasofoxifene combined with abemaciclib.

Repotrectinib is an investigational drug intended for the treatment of patients with advanced solid tumors harboring ROS1, NTRK1-3, or ALK molecular rearrangements.

Enhertu, or trastuzumab deruxtecan, will also receive accelerated assessment by the European Medicines Agency's Committee for Medicinal Products for Human Use.

In the Phase III ASCENT trial, antibody-drug conjugate Trodelvy was able to improve clinical outcomes in patients with relapsed or refractory metastatic TNBC who received at least two therapies prior.